By Judith E. Karp
This is a well timed compilation of latest suggestions within the molecular pathogenesis and molecular remedy of acute myelogenous leukemia (AML). the focal point is on chosen severe molecular determinants of AML pathogenesis and pathophysiology and the exploitation of those elements via diversified healing brokers and modalities. there's an emphasis all through at the bidirectional circulate of data among the medical and laboratory arenas.
Read Online or Download Acute Myelogenous Leukemia (Contemporary Hematology) PDF
Similar hematology books
Integrative drugs strives to include the easiest of complementary and traditional modalities. This publication information integrative oncology, a nascent box development a rigorous evidenced-based medical medication, examine, and academic origin. It examines 5 prestigious, accomplished melanoma facilities dependent within the US, protecting how those facilities begun their courses, what they're at present doing, and suggestions for beginning integrative medication clinics.
The impression of hormones on deep venous thrombosis is among the so much charged and debated matters. girl hormonal stability is basically plagued by using both oral contraceptives or HRT. for a very long time it's been well-known that oral contraceptives can elevate the prevalence of DVT; notwithstanding, there was an incredible controversy as to if all progestins do that both or no matter if a few have a better impression than others the place oral birth control is worried.
The publication is of curiosity to educational and commercial researchers but additionally clinicians who're engaged on irritation similar issues and wish to expand their wisdom approximately microarrays and the appliance thereof. After studying the publication a researcher or clinician will be within the place to devise, practice and examine or to seriously evaluate microarray experiments regarding irritation examine.
Additional resources for Acute Myelogenous Leukemia (Contemporary Hematology)
Our analysis also indicates that mutant CIEBPa RNAs are expressed at a higher level than wild-type ones in intermediaterisk patients , consistent with the absence of an antiproliferative effect and selection for an antiapoptotic effect. 8. l is an Ets family transcription factor required for both B lymphoid and myeloid development (116,117). Increased PD. 1 levels favor myeloid over lymphoid and monocyte over granulocyte commitment (118,119). 1 cofactors such as interferon consensus sequence binding protein/interferon response factor 8 (ICSBP/IRF-8) or c-Jun may account in part for the further commitment of the GMP to the monocytic lineage (122-124).
J Bioi Chern 1998;273:18,623-18,632. 191. Sebolt-Leopold JS. Development of anticancer drugs targeting the MAP kinase pathway. Oncogene 2000; 19:6594--6599. 192. Powis G, Bonjouklian R, Berggren MM, et al. Wortmannin, a potent and selective inhibitor of phosphatidylinositol-3- kinase. Cancer Res 1994;54:2419-2423. 193. Vlahos CJ, Matter WF, Hui KY, Brown RF. A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4- morpholinyl)-8-phenyl-4H-l-benzopyran-4-one (LY294002). J Bioi Chern 1994;269:5241-5248.
Feldman E, Kalaycio M, Weiner G, et al. Treatment of relapsed or refractory acute myeloid leukemia with humanized anti-CD33 monoclonal antibody HuM195. Leukemia 2003;17:314-318. 81. Feldman EJ, Brandwein J, Stone R, et al. Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, vs chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia. J Clin Oncol 2005;23(18):4110-4116. 82. Sievers EL, Appelbaum FR, Spielberger RT, et al.